We invite you to join our series of online presentations to learn about various science topics or find out more about our technologies, services and products.

Watch Dr. Schwenkert’s presentation on how our immune system deals with corona virus infections and how the complement system is involved.

The topic of this presentation is also available as a blog post.  

Watch the online presentation

7 April 2020

In the last couple of decades, there have been three major epidemics where animal viruses have infected humans. The most recent outbreak is caused by the SARS-CoV-2 virus, a.k.a. 2019-nCoV, which can result in corona virus disease 19 (COVID-19). Before this virus, there were outbreaks of SARS-CoV and MERS-CoV, which cause Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS), respectively.

6 April 2020

We invite you to join our series of online presentations to learn about various science topics or find out more about our technologies, services and products.

Watch Dr. Michael Schwenkert's presentation on IL-6, its biology and learn how IL-6 inhibitors have the potential to help COVID-19 patients with severe respiratory symptoms.

Watch the online presentation

2 April 2020

Wieslab Laboratory Services are proud to be one of the first diagnostic laboratories in Scandinavia to offer neurofilament light (NfL) testing in serum.

With the newest addition to our technology platform, we are able to use a single molecule array digital ELISA (SIMOA) to evaluate neurofilament light chain (NfL) in serum.

NfL is a well-known biomarker for measuring disease activity, treatment response and prognosis in patients with neurodegenerative disorders.

Being able to test NfL levels in serum facilitates patient care.

1 April 2020

The complement system is an important part of the innate immune system.There are three pathways by which it can be activated: the classical, lectin and the alternative pathway. All pathways converge at the level of Complement component C3 and eventually proceed to form aC5b-9 complex which might cause tissue damage at the site of activation.

30 March 2020

In recent years, there has been growing interest in the role of the complement system in transplantation medicine. Interestingly, the complement system is activated shortly after death occurs, which means that organs from deceased donors can contain complement components that trigger complement activation in the recipient. In addition, cold storage of organs awaiting transplantation can cause hypoxia, inflammation and tissue damage that activates the complement system and can contribute to graft loss and rejection.

26 March 2020

Svar Life Science working to set up ELISA tests for COVID-19 antibody detection 

As current events around COVID-19 continue to evolve, we're committed to contribute where we can. As a specialist laboratory and assay manufacturer, we are working hard to help address the urgent public health concerns by expanding the number of available COVID-19 antibody test possibilities.  

24 March 2020

The Interleukin 6 (IL-6) family is a large and diverse group of cytokines (IL-6, IL-11, IL-27, IL-31, OSM, LIF, CNTF, CT-1 and CLCF1) that is defined based on the use of common β-receptor signaling subunits. This family is very complex and affects most, if not all, major biological systems of the body. Its individual members are involved in reproduction, development tissue regeneration, immune homeostasis and defense against infection, trauma and injury. Not surprisingly, dysfunction in IL-6 family can lead to severe consequences such as chronic disease and cancer, which make them good candidates as diagnostic indicators, disease biomarkers and therapeutic targets.

20 March 2020

In a recent press release, Sanofi and Regeneron Pharmaceuticals, Inc announce that they have initiated a clinical program evaluating Kevzara® (sarilumab) in patients suffering from severe COVID-19. This drug is a monoclonal antibody that inhibits interleukin 6 (IL-6) by blocking its receptor. Preliminary data suggests that IL-6 may play an important role in driving acute respiratory distress syndrome (ARDS) in critically ill COVID-19 patients.

19 March 2020

To Our Customers & Business Partners, 

The COVID-19 outbreak is a serious health situation and we extend our sympathies to people who have lost loved ones, to patients and healthcare professionals around the world 

As concern is growing in our communities, businesses, and the world at-large; we want to ensure you of our commitment and ability to serve your business.  

Our focus has always been on delivering the solutions needed to provide answers in drug discovery and clinical diagnostics, and on the impact this has on human lives.  

18 March 2020

The complement system plays a key role in the immune defense against infection. In addition, it participates in the clearance of damaged cells and tissues and helps prevent cancer. However, uncontrolled complement activation may lead to life-threatening disorders, such as systemic inflammation and shock, dysregulation of coagulation/fibrinolysis, auto-aggression and under certain conditions tumorigenesis.

18 March 2020

Since drug development is expensive, many pharmaceutical companies have taken measures to speed up development to save time and money. Few of the novel drug candidates that have entered clinical evaluation during the past years have received marketing approval, with safety and efficacy being the major reasons for failure.The importance of biomarkers in improving drug development efficiency has since been emphasized and there has been a surge in the use of complement biomarkers in all phases of complement therapeutic drug development. 

16 March 2020

The clinical benefit of targeting the complement system has been established for many rare clinical disorders and the past few years have been a highly successful and exciting period for the field of complement-directed drug discovery and development. 

12 March 2020

The complement system is a key component of the body’s innate immune defense.It has an important role as a first-line defense against microorganisms but is also involved in other important functions such as homeostasis, clearance of cellular debris and immune surveillance.Clearly, such a broad range of functions requires a well-balanced interaction with other biological systems in the body.Indeed, the complement system has been likened to a balancing scale that needs to balance between providing sufficient activity to protect the body but not enough to be harmful.A number of genetic and environmental factors can tip the scale from defense to destruction.

10 March 2020

The complement system is an integral part of the innate immune response. Given its important role in many human disorders, complement activation measurements are important in a wide range of applications. 

The individual complement profile of a patient gives valuable information of the course and severity of a disease, and as a consequence, complement assays have evolved as essential tools not only in initial diagnosis but for following disease progression and monitoring complement-targeted therapies 

To determine whether deficiencies, overactivation and/or dysregulation in the complement system are causing, or contributing to, a person's disease or condition activity biomarkers can be used, and these types of tools have become increasingly available in routine clinical use.  

4 March 2020

Complement is an essential part of innate immunity. Disturbances in the complement system can lead to infections, inflammation and amplification of disease. Testing the functionality and activity of complement are powerful diagnostic tools and can also be used to verify the effect of treatment.

2 March 2020

Biosimilars have revolutionized the biopharmaceutical industry since they first appeared a little over a decade ago. They are medical products that are highly similar to an already approved reference product. In order for a biosimilar to be approved, the developer needs to demonstrate similarity to the reference product in key areas, such as pharmacokinetics, pharmacodynamics and evaluate efficacy, safety and immunogenicity in clinical studies.

27 February 2020

We are pleased to inform that, on February 21st 2020, Wieslab successfully received ISO 15189 accreditation by Swedac, replacing the previous ISO17025 accreditation held for over 20 years.  

24 February 2020

Biosimilars are biological medical products that are highly similar to already approved innovator drugs. In biosimilar development, the main goal is not to show safety and efficacy, but rather to demonstrate similarity to the innovator product in key areas, such as pharmacokinetics, pharmacodynamics and evaluation of efficacy, safety and immunogenicity in clinical studies. 

The FDA and its European counterpart, the EMA, as well as the World Health Organization have released guidelines on the development of biosimilars. All regulating bodies acknowledge the difficulties of biosimilar development. Each candidate drug has unique aspects that will require a case-by-case drug development program. For approval in the US, the biosimilar must be shown to be similar to the innovator product released on the US market and similarly, EU-approved biosimilars must be similar to their approved counterparts on the EU market. However, in order to facilitate global development programs, some foreign products are allowed in comparative clinical studies provided there is a scientific rationale of doing so. 

 

24 February 2020

A biosimilar is a biological medical product that is highly similar to an already approved “innovator” product. Unlike generics, which are identical copies of the approved product, biosimilars have small differences compared to the innovator product.  

The first biosimilar was approved in the EU in 2006 and since then a wide range of biosimilars have reached market. The FDA and its European counterpart, the EMA, have released strict guidelines on the development of biosimilars. Somewhat surprisingly, the main goal of a biosimilar clinical development program is not to show safety and efficacy, but rather to demonstrate similarity to the innovator product in key areas, such as pharmacokinetics, pharmacodynamics and evaluation of efficacy, safety and immunogenicity in clinical studies.  

21 February 2020